Share ownership Biotest AG Xetra

BIO3

DE0005227235

Pharmaceuticals

Market Closed - Xetra Other stock markets 11:10:14 2025-06-06 am EDT			5-day change	1st Jan Change
28.40 ^EUR	-3.40%		-.--%	-

Dec. 19

Grifols Wins US FDA Approval for Rare Blood Disorder Drug Fesilty

Share class: Biotest AG

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	19,785,726	19,785,726 ( 100 %)	0	51.43 %
Stock B	1	19,785,726	565,872 ( 2.86 %)	0

Major shareholders: Biotest AG

Name	Equities	%	Valuation
Axxion SA (Luxembourg) 0.2338 %	46,250	0.2338 %	2 M €
Knoesel & Ronge Vermögensverwaltung GmbH & Co. KG 0.2325 %	46,000	0.2325 %	2 M €
Monega Kapitalanlagegesellschaft mbH 0.2143 %	42,401	0.2143 %	2 M €
FPS Vermögensverwaltung GmbH 0.0212 %	4,200	0.0212 %	157 890 €

Name	Equities	%	Valuation
GRIFOLS, S.A. 97.14 %	19,219,854	97.14 %	837 M €
Arvernus Capital AG 0.0669 %	13,232	0.0669 %	576 137 €

Breakdown by shareholder type

Grifols SA	97.14%
Institutional	0.77%
Unknown	2.09%

Based on 1000 largest holdings

Geographical origin of shareholders

Spain	97.14%
Germany	0.47%
Luxembourg	0.23%
Switzerland	0.07%

Based on 1000 largest holdings

Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology, and intensive care medicine. It develops, manufactures, and markets immunoglobulin, coagulation factors, and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.

Employees

2,495

Sector

Pharmaceuticals

Calendar

Mar. 25 - Q4 2025 Earnings Release (Projected)

More about the company